18 results on '"Dalle, Jean‐Hugues"'
Search Results
2. Pubertal outcomes of children transplanted with allogeneic stem cells after myeloablative total body irradiation or busulfan: Influence of age and sex is confirmed, while a role of chronic graft‐versus‐host disease in delayed puberty onset is revealed
- Author
-
Weinhard, Sara, Wiedemann, Arnaud, Leheup, Bruno, Dalle, Jean‐Hugues, Lebon Labich, Béatrice, and Pochon, Cécile
- Subjects
TOTAL body irradiation ,DELAYED onset of disease ,STEM cell transplantation ,PRECOCIOUS puberty ,GRAFT versus host disease ,CHRONIC diseases ,HEMATOPOIETIC stem cell transplantation - Abstract
Introduction: Myeloablative conditioning before allogeneic HSCT during childhood exposes to serious long‐term complications, especially gonadal dysfunction. Pubertal issues are less described than other post‐HSCT sequelae in childhood. Methods: Pubertal development and biological gonadal parameters were assessed in a retrospective monocentric cohort of prepubertal patients who underwent HSCT after myeloablative conditioning with TBI or busulfan between 1981 and 2017. Results: Seventy‐four patients (28 girls and 46 boys) were included. No spontaneous pubertal development was found in 50% of girls and 10% of boys (P <.001), and delayed puberty or no spontaneous pubertal development was found in 57% of girls and 24% of boys (P =.009). HRT was used in 82% of girls and 24% of boys (P <.001). In univariate analysis, TBI conditioning (P =.05), female sex (P <.001), acute GVHD (P =.05), extensive chronic GVHD (P =.021), steroid treatment >6 months (P =.016), and malignant diseases (P =.016) were associated with no spontaneous pubertal development, whereas TBI conditioning (P =.003) and extensive chronic GVHD (P =.005) were associated with delayed puberty. In multivariate analysis, factors independently associated with no spontaneous puberty onset were female sex (P =.001) and age >10 years (P =.033). Factors independently associated with delayed puberty were extensive chronic GVHD (P =.041) and age >10 years (P =.031). Conclusion: This study highlighted the toxicity of MAC in prepubescent children: TBI did worse, but this was especially true for the most susceptible patients (girls, leukemic patients, and patients older than 10 years). It suggests a possible role of GVHD in delayed puberty. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
3. Pediatric acute graft‐versus‐host disease prophylaxis and treatment: surveyed real‐life approach reveals dissimilarities compared to published recommendations.
- Author
-
Lawitschka, Anita, Lucchini, Giovanna, Strahm, Brigitte, Dalle, Jean‐Hugues, Balduzzi, Adriana, Gibson, Brenda, Diaz De Heredia, Cristina, Wachowiak, Jacek, Dalissier, Arnaud, Vettenranta, Kim, Yaniv, Isaac, Bordon, Victoria, Bauer, Dorothea, Bader, Peter, Meisel, Roland, Peters, Christina, and Corbacioglu, Selim
- Subjects
GRAFT versus host disease ,THERAPEUTICS ,ACUTE diseases ,CELL transplantation ,DISEASE incidence - Abstract
Summary: Pediatric allogeneic hematopoietic cell transplantation (HCT) practices differ from those of adults, particularly the heterogeneity of transplantable nonmalignant diseases and the lower incidence of graft‐versus‐host disease (GVHD). Several guidelines regarding the management of acute (a) GVHD in adult HCT have been published. We aimed to capture the real‐life approaches for pediatric aGVHD prophylaxis/treatment, and data from 75/193 (response rate 39%) EBMT centers (26 countries) were included, representing half (48%) of the pediatric EBMT‐HCT activity. Results with ≥75% approval from respondents (74/75) for GVHD prophylaxis after myeloablative HCT for malignancies partially contradict published guidelines: Single‐agent cyclosporine A (CsA) was used for matched sibling donor HCT in 47%; blood CsA levels were reported lower; the relapse risk in malignant diseases influenced GVHD prophylaxis with early withdrawal of CsA; distinct longer duration of CsA was employed in nonmalignant diseases. Most centers used additional anti‐thymocyte globulin for matched unrelated and mismatched donor HCT, but not for matched siblings. Regarding prophylaxis in nonmyeloablative conditioning (mainly for nonmalignant diseases), responses showed broad heterogeneity. High conformity was found for first‐line treatment; however, results regarding steroid‐refractory aGVHD indicate an earlier diagnosis in children. Our findings highlight the need for standardized pediatric approaches toward aGVHD prophylaxis/treatment differentiated for malignant and nonmalignant underlying diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
4. "CRYOSTEM Biobank: A National Prospective, Standardized Collection to Better Characterize Allogeneic Hematopoietic Stem Cell Transplantation Complications".
- Author
-
Robert, Emilie, Fontenille, Claire, Dalle, Jean-Hugues, Peffault de Latour, Régis, and Calmels, Boris
- Subjects
BIOBANKS ,HEMATOPOIETIC stem cell transplantation ,GRAFT versus host disease ,MICROBIAL viability counts ,CRYOPRESERVATION of cells - Abstract
CRYOSTEM was initiated in 2010 to create a multicenter biobank in the field of Hematopoietic Stem Cell Transplantation (HSCT). After initially concentrating on Graft-versus-Host Disease, CRYOSTEM has broadened its focus to all HSCT complications. Thanks to a network of 33 transplant units and 23 Biological Resources Centers, CRYOSTEM has established a standardized collection of high-quality biological samples associated with well-annotated clinical data from donors and patients pre- and post-HSCT. Plasma, dried pellets and viable cells in DMSO are isolated and cryopreserved from blood samples. Currently, the collection has reached almost 200,000 available samples coming from nearly 5,800 patients. Since 2015, CRYOSTEM has provided the national and international scientific community with these samples for largescale research to improve the knowledge of HSCT complications. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
5. Association of Matched Sibling Donor Hematopoietic Stem Cell Transplantation With Transcranial Doppler Velocities in Children With Sickle Cell Anemia.
- Author
-
Bernaudin, Françoise, Verlhac, Suzanne, Peffault de Latour, Régis, Dalle, Jean-Hugues, Brousse, Valentine, Petras, Eléonore, Thuret, Isabelle, Paillard, Catherine, Neven, Bénédicte, Galambrun, Claire, Divialle-Doumdo, Lydia, Pondarré, Corinne, Guitton, Corinne, Missud, Florence, Runel, Camille, Jubert, Charlotte, Elana, Gisèle, Ducros-Miralles, Elisabeth, Drain, Elise, and Taïeb, Olivier
- Subjects
HEMATOPOIETIC stem cell transplantation ,TRANSCRANIAL Doppler ultrasonography ,SICKLE cell anemia in children ,STEM cell donors ,SICKLE cell anemia treatment ,BLOOD flow measurement ,SIBLINGS ,CEREBRAL circulation ,COMPARATIVE studies ,FERRITIN ,GRAFT versus host disease ,HEMODYNAMICS ,HOMOGRAFTS ,IMMUNOSUPPRESSION ,RESEARCH methodology ,MEDICAL cooperation ,PROBABILITY theory ,QUALITY of life ,RESEARCH ,SICKLE cell anemia ,EVALUATION research ,RANDOMIZED controlled trials - Abstract
Importance: In children with sickle cell anemia (SCA), high transcranial Doppler (TCD) velocities are associated with stroke risk, which is reduced by chronic transfusion. Whether matched sibling donor hematopoietic stem cell transplantation (MSD-HSCT) can reduce velocities in patients with SCA is unknown.Objective: To determine the association of MSD-HSCT with TCD velocities as a surrogate for the occurrence of ischemic stroke in children with SCA.Design, Setting, and Participants: Nonrandomized controlled intervention study conducted at 9 French centers. Patients with SCA were enrolled between December 2010 and June 2013, with 3-year follow-up ending in January 2017. Children with SCA were eligible if younger than 15 years, required chronic transfusions for persistently elevated TCD velocities, and had at least 1 sibling without SCA from the same 2 parents. Families agreed to HLA antigen typing and transplantation if a matched sibling donor was identified or to standard care in the absence of a matched sibling donor.Exposures: MSD-HSCT (n = 32), compared with standard care (n = 35) (transfusions for ≥1 year with potential switch to hydroxyurea thereafter), using propensity score matching.Main Outcomes and Measures: The primary outcome was the highest time-averaged mean of maximum velocities in 8 cerebral arteries, measured by TCD (TCD velocity) at 1 year. Twenty-five of 29 secondary outcomes were analyzed, including the highest TCD velocity at 3 years and normalization of velocities (<170 cm/s) and ferritin levels at 1 and 3 years.Results: Sixty-seven children with SCA (median age, 7.6 years; 35 girls [52%]) were enrolled (7 with stroke history). In the matched sample, highest TCD velocities at 1 year were significantly lower on average in the transplantation group (129.6 cm/s) vs the standard care group (170.4 cm/s; difference, -40.8 cm/s [95% CI, -62.9 to -18.6]; P < .001). Of the 25 analyzed secondary end points, 4 showed significant differences, including the highest TCD velocity at 3 years (112.4 cm/s in the transplantation group vs 156.7 cm/s in the standard care group; difference, -44.3 [95% CI, -71.9 to -21.1]; P = .001); normalization rate at 1 year (80.0% in the transplantation group vs 48.0% in the standard care group; difference, 32.0% [95% CI, 0.2% to 58.6%]; P = .045); and ferritin levels at 1 year (905 ng/mL in the transplantation group vs 2529 ng/mL in the standard care group; difference, -1624 [95% CI, -2370 to -879]; P < .001) and 3 years (382 ng/mL in the transplantation group vs 2170 ng/mL in the standard care group; difference, -1788 [95% CI, -2570 to -1006]; P < .001).Conclusions and Relevance: Among children with SCA requiring chronic transfusion because of persistently elevated TCD velocities, MSD-HSCT was significantly associated with lower TCD velocities at 1 year compared with standard care. Further research is warranted to assess the effects of MSD-HSCT on clinical outcomes and over longer follow-up.Trial Registration: ClinicalTrials.gov Identifier: NCT01340404. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
6. Allogeneic Stem Cell Transplantation from HLA-Mismatched Donors for Pediatric Patients with Acute Lymphoblastic Leukemia Treated According to the 2003 BFM and 2007 International BFM Studies: Impact of Disease Risk on Outcomes.
- Author
-
Dalle, Jean-Hugues, Balduzzi, Adriana, Bader, Peter, Lankester, Arjan, Yaniv, Isaac, Wachowiak, Jacek, Pieczonka, Anna, Bierings, Marc, Yesilipek, Akif, Sedlaçek, Petr, Ifversen, Marianne, Sufliarska, Sabina, Toporski, Jacek, Glogova, Evgenia, Poetschger, Ulrike, and Peters, Christina
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *LYMPHOBLASTIC leukemia , *CHILD patients , *GRAFT versus host disease , *CYTOMEGALOVIRUSES , *CORD blood , *DISEASE remission , *MULTIVARIATE analysis - Abstract
Abstract Allogeneic hematopoietic stem cell transplantation (HSCT) is beneficial for pediatric patients with relapsed or (very) high-risk acute lymphoblastic leukemia (ALL) in remission. A total of 1115 consecutive patients were included in the ALL SCT 2003 BFM study and the ALL SCT 2007 I-BFM study and were stratified according to relapse risk (standard versus high versus very high risk of relapse) and donor type (matched sibling versus matched donor versus mismatched donor). A total of 148 patients (60% boys; median age, 8.7 years; B cell precursor ALL, 75%) were transplanted from mismatched donors, which was defined as either less than 9/10 HLA-compatible donors or less than 5/6 unrelated cord blood after myeloablative conditioning regimen (total body irradiation based, 67%) for high relapse risk (HRR; n = 42) or very HRR (VHRR) disease (n = 106). The stem cell source was either bone marrow (n = 31), unmanipulated peripheral stem cells (n = 28), T cell ex vivo depleted peripheral stem cells (n = 59), or cord blood (n = 25). The median follow-up was 5.1 years. The 4-year rates of overall survival (OS) and event-free survival were 56% ± 4% and 52% ± 4%, respectively, for the entire cohort. Patients transplanted from mismatched donors for HRR disease obtained remarkable 4-year OS and event-free survival values of 82% ± 6% and 80% ± 6%, respectively, whereas VHRR patients obtained values of 45% ± 5% and 42% ± 5% (P <.001), respectively. The cumulative incidence of relapse was 29% ± 4% and that of nonrelapse mortality 19% ± 3%. The cumulative incidence of limited and extensive chronic graft-versus-host disease was 13% ± 3% and 15% ± 4%, respectively, among the 120 patients living beyond day 100. Multivariate analysis showed that OS was lower for transplanted VHRR patients (P =.002; hazard ratio [HR], 3.62; 95% confidence interval [CI], 1.60 to 8.20) and for patients beyond second complete remission (CR2) versus first complete remission (P <.001; HR, 3.68; 95% CI, 1.79 to 7.56); relapse occurred more frequently in patients with VHRR disease (P =.026; HR, 3.30; 95% CI, 1.16 to 9.60) and for those beyond CR2 (P =.005; HR, 4.16; 95% CI, 1.52 to 10.59). Nonrelapse mortality was not significantly higher for cytomegalovirus-positive recipients receiving cytomegalovirus-negative grafts (P =.12; HR, 1.96; 95% CI,.84 to 4.58). HSCT with a mismatched donor is feasible in pediatric ALL patients but leads to inferior results compared with HSCT with better matched donors, at least for patients transplanted for VHRR disease. The results are strongly affected by disease status. The main cause of treatment failure is still relapse, highlighting the urgent need for interventional strategies after HSCT for patients with residual leukemia before and/or after transplantation [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
7. Low Body Mass Index Is Associated with Increased Risk of Acute GVHD after Umbilical Cord Blood Transplantation in Children and Young Adults with Acute Leukemia: A Study on Behalf of Eurocord and the EBMT Pediatric Disease Working Party.
- Author
-
Paviglianiti, Annalisa, Dalle, Jean Hugues, Ayas, Mouhab, Boelens, Jan Jaap, Volt, Fernanda, Iori, Anna Paola, de Souza, Mair Pedro, Diaz, Miguel Angel, Michel, Gerard, Locatelli, Franco, Jubert, Charlotte, Yakoub-Agha, Ibrahim, Bittencourt, Henrique, Bertrand, Yves, Kenzey, Chantal, Tozatto Maio, Karina, Hayashi, Hiromi, Rocha, Vanderson, Bader, Peter, and Gluckman, Eliane
- Subjects
- *
BODY mass index , *GRAFT versus host disease , *HEMATOPOIETIC stem cell transplantation , *UMBILICAL cord , *LEUKEMIA - Abstract
Body mass index (BMI) may influence outcomes after allogeneic hematopoietic stem cell transplantation (HSCT). However, the impact of BMI on survival in children undergoing HSCT is not well defined, with conflicting results being reported on this issue. We analyzed 855 patients age 2 to 20 years with diagnosis of acute leukemia who underwent umbilical cord blood transplantation (UCBT) from 1990 to 2015. Patients were classified according to BMI as normal (fifth to 85th percentile), underweight (less than fifth percentile), overweight (85th to 95th percentile), and obese (>95th percentile) using growth charts for age and sex. All patients received single-unit UCBT after a myeloablative conditioning regimen. Diagnosis was acute lymphoblastic leukemia in 68% of the patients. Sixty-one percent of patients (n = 523) were in the normal BMI category, 11% (n = 96) were underweight, 16% (n = 137) overweight, and 12% (n = 99) obese. The cumulative incidence of grade II to IV acute graft-versus-host disease (aGVHD) was 35% (32% to 38%). According to pretransplantation BMI, aGVHD was 46% (33% to 59%) for underweight, 34% (31% to 42%) for normal, 36% (18% to 38%) for overweight, and 27% (15% to 37%) for obese ( P = .04). In multivariate analysis, a BMI less than the fifth percentile was associated with higher incidence of acute grade II to IV GVHD compared with normal-BMI patients (hazard ratio, 1.61; 95% confidence interval, 1.15 to 2.26; P = .006). Our results show that being underweight at the time of transplantation is associated with an increased risk of aGVHD, highlighting the importance of nutritional status before UCBT. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
8. Relationship between cytomegalovirus ( CMV) reactivation, CMV-driven immunity, overall immune recovery and graft-versus-leukaemia effect in children.
- Author
-
Jeljeli, Mohamed, Guérin‐El Khourouj, Valérie, Porcher, Raphael, Fahd, Mony, Leveillé, Sandrine, Yakouben, Karima, Ouachée‐Chardin, Marie, LeGoff, Jerome, Cordeiro, Debora Jorge, Pédron, Beatrice, Baruchel, Andre, Dalle, Jean‐Hugues, and Sterkers, Ghislaine
- Subjects
CYTOMEGALOVIRUSES ,IMMUNITY ,GRAFT versus host disease ,LEUKEMIA in children ,HEMATOPOIETIC stem cells ,FOLLOW-up studies (Medicine) - Abstract
The interplay between immune recovery, cytomegalovirus ( CMV)-reactivation, CMV-driven immunity and graft-versus-leukaemia effect ( GVL) was analysed in 108 children (median age: 8 years) who underwent haematopoietic-stem cell transplantation ( HSCT) for acute leukaemia. Follow-up was 2 years unless death or relapse occurred. CMV-polymerase chain reaction ( PCR) was programmed weekly until month +3 post- HSCT. Immunomonitoring consisted of sequential lymphocyte subset enumerations and analyses of T-cell proliferative and γ-interferon responses to CMV and to adenovirus. In the 108 recipients, the 2-year relapse rate ( RR) was 25% (median time to onset 4·5 months; range: 24 d-17 months). CMV reactivation occurrence was 31% (median time to onset 26 d). Donor/recipient CMV serostatus did not influence RR. Among the 89 recipients disease-free after day +120, i) early CMV-reactivation before day +30 was more frequent ( P = 0·01) in the relapse recipient group opposed to the non-relapse group. ii) CD8
+ / CD28− and CD4+ CD45 RA− T-cell expansions induced by CMV did not influence RR, iii) Recovery of anti- CMV and also anti-adenovirus immunity and of naïve CD4+ T-cells was faster in the non-relapse group ( P = 0·008; 0·009 and 0·002 respectively). In contrast to adult acute myeloid leukaemia, CMV reactivation was associated with increased RR in this paediatric series. Accelerated overall immune recovery rather than CMV-driven immunity had a favourable impact on RR. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
9. Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the European Group for Blood and Marrow Transplantation experience.
- Author
-
de Latour, Régis Peffault, Porcher, Raphael, Dalle, Jean-Hugues, Aljurf, Mahmoud, Korthof, Elisabeth T., Svahn, Johanna, Willemze, Roelof, Barrenetxea, Cristina, Mialou, Valerie, Soulier, Jean, Ayas, Mouhab, Oneto, Rosi, Bacigalupo, Andrea, Marsh, Judith C. W., Peters, Christina, Socie, Gerard, and Dufour, Carlo
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *FANCONI'S anemia , *FLUDARABINE , *BONE marrow transplantation , *BLOOD transfusion , *TRANSPLANTATION of organs, tissues, etc. , *MEDICAL protocols , *GRAFT versus host disease , *THERAPEUTICS - Abstract
Although allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative treatment for patients with Fanconi anemia (FA), published series mostly refer to single-center experience with limited numbers of patients. We analyzed results in 795 patients with FA who underwent first HSCT between May 1972 and January 2010. With a 6-year median follow-up, overall survival was 49% at 20 years (95% confidence interval, 38-65 years). Better outcome was observed for patients transplanted before the age of 10 years, before clonal evolution (ie, myelodysplastic syndrome or acute myeloid leukemia), from a matched family donor, after a conditioning regimen without irradiation, the latter including fludarabine. Chronic graft-versus-host disease and secondary malignancy were deleterious when considered as time-dependent covariates. Age more than 10 years at time of HSCT, clonal evolution as an indication for transplantation, peripheral blood as source of stem cells, and chronic graft-versus-host disease were found to be independently associated with the risk for secondary malignancy. Changes in transplant protocols have significantly improved the outcome of patients with FA, who should be transplanted at a young age, with bone marrow as the source of stem cells. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
10. Survival and Functional Outcomes in Boys with Cerebral Adrenoleukodystrophy with and without Hematopoietic Stem Cell Transplantation.
- Author
-
Raymond, Gerald V., Aubourg, Patrick, Paker, Asif, Escolar, Maria, Fischer, Alain, Blanche, Stephane, Baruchel, André, Dalle, Jean-Hugues, Michel, Gérard, Prasad, Vinod, Miller, Weston, Paadre, Susan, Balser, John, Kurtzberg, Joanne, Nascene, David R., Orchard, Paul J., and Lund, Troy
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *ADRENOLEUKODYSTROPHY , *THERAPEUTICS , *GRAFT versus host disease , *MAGNETIC resonance imaging - Abstract
Highlights • Hematopoietic stem cell transplantation (HSCT) significantly improves survival in patients with cerebral adrenoleukodystrophy. • When performed early in the course of disease, HSCT improves major functional disability-free survival ABSTRACT Cerebral adrenoleukodystrophy (CALD) is a rapidly progressing, often fatal neurodegenerative disease caused by mutations in the ABCD1 gene, resulting in deficiency of ALD protein. Clinical benefit has been reported following allogeneic hematopoietic stem cell transplantation (HSCT). We conducted a large multicenter retrospective chart review to characterize the natural history of CALD, to describe outcomes after HSCT, and to identify predictors of treatment outcomes. Major functional disabilities (MFDs) were identified as having the most significant impact on patients' abilities to function independently and were used to assess HSCT outcome. Neurologic function score (NFS) and Loes magnetic resonance imaging score were assessed. Data were collected on 72 patients with CALD who did not undergo HSCT (untreated cohort) and on 65 patients who underwent transplantation (HSCT cohort) at 5 clinical sites. Kaplan-Meier (KM) estimates of 5-year overall survival (OS) from the time of CALD diagnosis were 55% (95% confidence interval [CI], 42.2% to 65.7%) for the untreated cohort and 78% (95% CI, 64% to 86.6%) for the HSCT cohort overall (P =.01). KM estimates of 2-year MFD-free survival for patients with gadolinium-enhanced lesions (GdE+) were 29% (95% CI, 11.7% to 48.2%) for untreated patients (n = 21). For patients who underwent HSCT with GdE+ at baseline, with an NFS ≤1 and Loes score of 0.5 to ≤9 (n = 27), the 2-year MFD-free survival was 84% (95% CI, 62.3% to 93.6%). Mortality rates post-HSCT were 8% (5 of 65) at 100days and 18% (12 of 65) at 1 year, with disease progression (44%; 7 of 16) and infection (31%; 5 of 16) listed as the most common causes of death. Adverse events post-HSCT included infection (29%; 19 of 65), acute grade II-IV graft-versus-host disease (GVHD) (31%; 18 of 58), and chronic GVHD (7%; 4 of 58). Eighteen percent of the patients (12 of 65) experienced engraftment failure after their first HSCT. Positive predictors of OS in the HSCT cohort may include donor-recipient HLA matching and lack of GVHD, and early disease treatment was predictive of MFD-free survival. GdE+ status is a strong predictor of disease progression in untreated patients. This study confirms HSCT as an effective treatment for CALD when performed early. We propose survival without MFDs as a relevant treatment goal, rather than solely assessing OS as an indicator of treatment success. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
11. Long-Term Outcomes of Cord Blood Transplantation from an HLA-Identical Sibling for Patients with Bone Marrow Failure Syndromes: A Report From Eurocord, Cord Blood Committee and Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation
- Author
-
Pagliuca, Simona, Peffault de Latour, Régis, Bertrand, Yves, Diaz de Heredia, Cristina, Nagler, Arnon, Ghavamzadeh, Ardeshir, Sufliarska, Sabina, Lawson, Sarah, Dufour, Carlo, Passweg, Jakob, Rocha, Vanderson, Volt, Fernanda, Kenzey, Chantal, Gluckman, Eliane, Ruggeri, Annalisa, Locatelli, Franco, Zecca, Marco, Comoli, Patrizia, Dalle, Jean-Hugues, and Vettenranta, Kim
- Subjects
- *
CORD blood transplantation , *HLA histocompatibility antigens , *BONE marrow diseases , *HEALTH outcome assessment , *GRAFT versus host disease , *SIBLINGS , *DISEASE risk factors , *DISEASES - Abstract
Cord blood transplantation (CBT) from HLA-identical siblings is an attractive option for patients with bone marrow failure (BMF) syndrome because of the low risk of graft-versus-host disease (GVHD) and the absence of risk to the donor. We analyzed outcomes of 117 patients with inherited or acquired BMF syndrome who received CBT from a related HLA-identical donor in European Society for Blood and Marrow Transplantation centers between 1988 and 2014. Ninety-seven patients had inherited and 20 patients acquired BMF syndrome. Eighty-two patients received a single cord blood (CB) unit, whereas 35 patients received a combination of CB and bone marrow cells from the same donor. Median age at CBT was 6.7 years, and median follow-up was 86.7 months. The cumulative incidence function (CIF) of neutrophil recovery was 88.8% (95% CI, 83.1% to 94.9%), 100-day CIF of grades II to IV acute GVHD was 15.2%, and 7-year CIF of chronic GVHD was 14.5%. Overall survival at 7 years was 87.9% (95% CI, 80.8% to 92.6%), 89% for inherited and 81% for acquired BMF syndromes ( P = .66). Results of this study are consistent with outcomes of bone marrow transplantation shown by previous series in the same setting and indicate that in pediatric patients with BMF syndrome, CBT from an HLA-identical sibling donor is associated with excellent long-term outcomes and that collection of CB unit at birth of a new sibling is strongly recommended. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
12. Unrelated Cord Blood Transplantation for Acute Leukemia Diagnosed in the First Year of Life: Outcomes and Risk Factor Analysis.
- Author
-
Ruggeri, Annalisa, Volt, Fernanda, Locatelli, Franco, Michel, Gerard, Diaz de Heredia, Cristina, Abecasis, Manuel, Zecca, Marco, Vora, Ajay, Yakouben, Karima, O'Brien, Tracey A., Giardino, Stefano, Cornish, Jacqueline, Rocha, Vanderson, Peters, Christina, Bader, Peter, Gluckman, Eliane, and Dalle, Jean Hugues
- Subjects
- *
CORD blood transplantation , *ACUTE leukemia , *RISK assessment , *GRAFT versus host disease , *ACUTE myeloid leukemia - Abstract
Infant acute leukemia still has a poor prognosis, and allogeneic hematopoietic stem cell transplantation is indicated in selected patients. Umbilical cord blood (UCB) is an attractive cell source for this population because of the low risk of chronic graft-versus-host disease (GVHD), the strong graft-versus-leukemia effect, and prompt donor availability. This retrospective, registry-based study reported UCB transplantation (UCBT) outcomes in 252 children with acute lymphoblastic leukemia (ALL; n = 157) or acute myelogenous leukemia (AML; n = 95) diagnosed before 1 year of age who received a single-unit UCBT after myeloablative conditioning between 1996 and 2012 in European Society for Blood and Marrow Transplantation centers. Median age at UCBT was 1.1 years, and median follow-up was 42 months. Most patients (57%) received a graft with 1 HLA disparity and were transplanted in first complete remission (CR; 55%). Cumulative incidence function (CIF) of day 100 acute GVHD (grades II to IV) was 40% ± 3% and of 4-year chronic GVHD was 13% ± 2%. CIF of 1-year transplant-related mortality was 23% ± 3% and of 4-year relapse was 27% ± 3%. Leukemia-free-survival (LFS) at 4 years was 50% ± 3%; it was 40% and 66% for those transplanted for ALL and AML, respectively ( P = .001). LFS was better for patients transplanted in first CR, regardless of diagnosis. In multivariate model, diagnosis of ALL ( P = .001), advanced disease status at UCBT (<.001), age at diagnosis younger than 3 months ( P = .012), and date of transplant before 2004 were independently associated with worse LFS. UCBT is a suitable option for patients diagnosed with infant acute leukemia who achieve CR. In this cohort, patients with AML had better survival than those with ALL. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
13. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation.
- Author
-
Groll, Andreas H., Castagnola, Elio, Cesaro, Simone, Dalle, Jean-Hugues, Engelhard, Dan, Hope, William, Roilides, Emmanuel, Styczynski, Jan, Warris, Adilia, and Lehrnbecher, Thomas
- Subjects
- *
LEUKEMIA treatment , *MYCOSES , *GRAFT versus host disease , *HEMATOPOIETIC system , *STEM cell transplantation , *COMORBIDITY - Abstract
Invasive opportunistic fungal diseases (IFDs) are important causes of morbidity and mortality in paediatric patients with cancer and those who have had an allogeneic haemopoietic stem-cell transplantation (HSCT). Apart from differences in underlying disorders and comorbidities relative to those of adults, IFDs in infants, children, and adolescents are unique with respect to their epidemiology, the usefulness of diagnostic methods, the pharmacology and dosing of antifungal agents, and the absence of interventional phase 3 clinical trials for guidance of evidence-based decisions. To better define the state of knowledge on IFDs in paediatric patients with cancer and allogeneic HSCT and to improve IFD diagnosis, prevention, and management, the Fourth European Conference on Infections in Leukaemia (ECIL-4) in 2011 convened a group that reviewed the scientific literature on IFDs and graded the available quality of evidence according to the Infectious Diseases Society of America grading system. The final considerations and recommendations of the group are summarised in this manuscript. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
14. Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling.
- Author
-
Locatelli, Franco, Kabbara, Nabil, Ruggeri, Annalisa, Ghavamzadeh, Ardeshir, Roberts, Irene, Chi Kong Li, Bernaudin, Françoise, Vermylen, Christiane, Dalle, Jean-Hugues, Stein, Jerry, Wynn, Robert, Cordonnier, Catherine, Pinto, Fernando, Angelucci, Emanuele, Socié, Gérard, Gluckman, Eliane, Walters, Mark C., and Rocha, Vanderson
- Subjects
- *
HEALTH outcome assessment , *CORD blood transplantation , *BONE marrow transplantation , *SICKLE cell anemia , *BETA-Thalassemia , *GRAFT versus host disease , *PATIENTS , *THERAPEUTICS - Abstract
We analyzed the outcomes of 485 patients with thalassemia major (TM) or sickle cell disease (SCO) receiving HLA-identical sibling cord blood transplantation (CBT, n = 96) or bone marrow transplantation (BMT, n = 389). Compared with patients given BMT, CBT recipients were significantly younger (median age 6 vs 8 years, P = .02), and were treated more recently (median year 2001 vs 1999, P< .01). A higher proportion of patients with TM belonging to classes ll-lll of the Pesaro classification received BMT (44%) compared with CBT (39%, P< .01). In comparison with patients receiving BMT (n = 259, TM; n = 130, SCD), those given CBT (n = 66, TM; n = 30, SCD) had slower neutrophil recovery, less acute graft-versus-host disease (GVHD) and none had extensive chronic GVHO. With a median follow-up of 70 months, the 6-year overall survival was 95% and 97% after BMT and CBT, respectively (P = .92). The 6-year disease-free survival (DFS) was 86% and 80% in TM patients after BMT and CBT, respectively, whereas DFS in SCD patients was 92% and 90%, respectively. The cell dose infused did not influence outcome of patients given CBT. In multivariate analysis, DFS did not differ between CBT and BMT recipients. Patients with TM or SCD have excellent outcomes after both HLA-identical sibling CBT and BMT. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
15. Cellular and humoral immunity elicited by influenza vaccines in pediatric hematopoietic-stem cell transplantation
- Author
-
Guérin-El Khourouj, Valérie, Duchamp, Marie, Krivine, Anne, Pédron, Béatrice, Ouachée-Chardin, Marie, Yakouben, Karima, Frémond, Marie-Louise, Baruchel, André, Dalle, Jean-Hugues, and Sterkers, Ghislaine
- Subjects
- *
CELLULAR immunity , *GRAFT versus host disease , *INFLUENZA vaccines , *PEDIATRICS , *HEMATOPOIETIC stem cell transplantation , *T cells , *HEMAGGLUTININ , *CYTOKINES - Abstract
Abstract: Immunity induced by influenza vaccines following hematopoietic stem-cell transplantation (HSCT) is poorly understood. Here, 14 pediatric recipients (mean age: 6years) received H1N1 (n =9) or H1N1/H3N2 (n =5) vaccines at a median of 5.7months post-HSCT (HLA-identical related bone-marrow graft: 10/14). Fourteen clinically-matched non-vaccinated recipients were included as controls. Cellular response to vaccination was assessed by a T-cell proliferation assay. Humoral response was assessed by H1N1-specific antibody titration. IL2 and IFNγ responses to influenza were also evaluated by an intracellular cytokine accumulation method for some of the recipients. Higher proliferative responses to H1N1 (p =0.0001) and higher H1N1-specific antibody titers (p <0.02) were observed in vaccines opposed to non-vaccinated recipients. In some cases, proliferative responses to H1N1 developed while at the same time antibody titers did not reach protective (⩾1:40) levels. Most recipients vaccinated with only the H1N1 strain had proliferative responses to both H1N1 and H3N2 (median stimulation index H1N1: 96, H3N2: 126 in responders). Finally, IL2 responses predominated over IFNγ responses (p <0.02) to influenza viruses in responders. In conclusion, H1N1 vaccination induced substantial cell-mediated immunity, and to a lesser extent, humoral immunity at early times post-HSCT. H1N1/H3N2 T-cell cross-reactivity and protective (IL2) rather than effector (IFNγ) cytokinic profiles were elicited. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
16. Outcome of Children Developing Grade III-IV Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.
- Author
-
Bertaina, Alice, Locatelli, Franco, Galimard, Jacques-Emmanuel, Lawitschka, Anita, Balduzzi, Adriana, Dalle, Jean-Hugues, Sedlacek, Petr, Willasch, Andre, Yaniv, Isaac, Labopin, Myriam, Peters, Christina, and Bader, Peter
- Subjects
- *
GRAFT versus host disease , *HEMATOPOIETIC stem cell transplantation , *CHILD patients , *CHILD mortality , *MEDICAL registries - Abstract
Acute graft versus host disease (aGvHD) remains one of the major causes of procedure-related morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). Information on the outcome of pediatric patients experiencing this complication is limited. We conducted a retrospective registry-based analysis on children who developed grade III-IV acute GVHD and were reported to the European Blood and Marrow Transplantation (EBMT) registry. Included in the study were children below age of 18 years who were transplanted between 2004 and 2016 (n=28109). Of these children, 1968 experienced grade III-IV acute GvHD: 1370 were had malignancies, while 598 were affected by a non-malignant disorder (NMD). Median year at HSCT was 2009 for patients with malignancies and 2010 for patients with NMD. In this latter group, as expected, the median age at HSCT was lower (5.8 years), in comparison with those affected by malignancies (9 years). The donor was an HLA-identical sibling in 576 cases and an unrelated donor in 895 cases. Umbilical cord blood (UCB) was employed in 282 cases, while a relative other than a compatible sibling in 215 cases. Overall, 1075 patients were given bone marrow (BM), while 598 received peripheral blood stem cells (PBSC). A fully myeloablative conditioning regimen has been employed in 94% of patients with malignancies in comparison with 75% of children with NMD. As a post-transplant pharmacological GvHD prophylaxis, a different strategy of immune suppressive treatment have been used: it consisted in the association of Cyclosporine-A (CSA) and Methotrexate in 40%, CSA alone in 30% and CSA plus Mycophenolate mofetil in 10% of patients. Grade III aGvHD occurred in 1383 patients (70%), while grade IV aGvHD was diagnosed in 585 (30%). Chronic GvHD occurred in 48.2% and 49.3% of patients with malignant and NMD, respectively. It was extensive in 262 (26.8%) patients with malignancies and in 111 (28%) children affected by NMD. Within patients with malignancies, the 2-year Kaplan-Meyer probability of overall survival (OS) was 65.7% (confidence interval 95, 63 - 68.4). In this group, the cumulative incidence of non-relapse mortality (NRM) was 23.1%. Notably, the occurrence of GvHD was responsible of death in 228 patients (CI 14.5%). In the NMD cohort, the 2-year Kaplan-Meyer probability of overall survival (OS) was 67.8% (confidence interval 95, 63.8 - 71.9). Sixty-one patients died to GvHD, being the 2-year cumulative incidence of GvHD-related mortality 19%. These data indicate that the occurrence of grade III-IV aGVHD is associated with a dismal outcome also in pediatric patients. The main cause of fatality is represented by NRM, while leukemia recurrence affected outcome of a lower number of children. Thus, strategies aimed at preventing this immune-mediated complication and at optimizing its treatment are desirable. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
17. 4 - Monitoring of MRD before and after Allogeneic Hematopoietic Cell Transplantation (HCT) of Childhood ALL by FC and RQ-PCR: A Retrospective Assessment on Behalf of the Pdwp of the Ebmt, the Cog, the Pbmtc, the I-Bfm and the Westhafen-Intercontinental-Group
- Author
-
Bader, Peter, Salzmann-Manrique, Emilia, Sr., Adriana Balduzzi, Dalle, Jean-Hugues, Woolfrey, Ann E., Bar, Merav, Verneris, Michael R., Borowitz, Michael J., Shah, Nirali N., Gossai, Nathan, Shaw, Peter John, Chen, Allen R., Kreyenberg, Hermann, Di Maio, Lucia, Eckert, Cornelia, van der Velden, Vincent H.J., Lankester, Arjan, Klingebiel, Thomas E., Peters, Christina, and Grupp, Stephan A.
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *GRAFT versus host disease , *PATIENT monitoring , *POLYMERASE chain reaction , *MULTIVARIATE analysis - Published
- 2017
- Full Text
- View/download PDF
18. Limited efficacy and tolerance of imatinib mesylate in steroid-refractory scierodermatous chronic GVHD.
- Author
-
de Masson, Adele, Bouaziz, Jean-Oavid, de Latour, Régis Peffault, Wittnebel, Sebastian, Ribaud, Patricia, Rubio, Mane-Thérèse, Micol, Jean-Baptiste, Suarez, Felipe, Nguyen, Stéphanie, Dalle, Jean-Hugues, Yakouben, Karima, Robin, Marie, Xhaard, Aliénor, Adès, Lionel, Bourtils, Jean-Henn, Rybojad, Michel, Bagot, Martine, and Socie, Gerard
- Subjects
- *
IMATINIB , *GRAFT versus host disease , *PROTEIN-tyrosine kinases , *GRAFT versus host reaction , *THERAPEUTICS , *RETROSPECTIVE studies - Abstract
The article focuses on the use of imatinib mesylate (IM) which is a tyrosine kinase inhibitor which is effective for treating of chronic graft versus host disease (cGVDH). It highlights the retrospective study to asses the long-term effectiveness of IM for sclerodermatous cGVDH in hospitals in France. Results of the study suggest that IM has limited efficacy and tolerance in sclerodermatous cGVDH and the few patients may benefit from IM treatment.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.